Serono's Dealmaking Roll continues
Serono's licensing of the exclusive rights to market Genentech Inc.'s Phase III psoriasis drug, Raptiva, outside of the US, Japan, and certain Asian countries, went far to quell rumblings within the investment community that the Swiss-based biotech needed to beef up its late-stage pipeline. The agreement also comes amidst a flurry of dealmaking which sends a clear message that the company's management is willing to act aggressively to fill in gaps in all aspects of the business from discovery to product development to commercialization.
You may also be interested in...
Analysts generally expressed the view that Pfizer and Serono will both benefit from their agreement to co-promote the multiple sclerosis drug, Rebif. But some question whether the sales and marketing boost Pfizer will give the specialty drug justifies its $200 million upfront payment, or, for that matter, the estimated 35%-40% commission on sales that Serono will be required to pay Pfizer.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.